Loading organizations...
REGENXBIO is a clinical-stage biotechnology company developing gene therapies. It leverages its proprietary NAV Technology Platform, using adeno-associated virus (AAV) vectors, to create targeted treatments for severe genetic diseases. This platform enables precise delivery of therapeutic genes to modify gene expression, aiming for long-lasting effects across various conditions.
Founded in 2009, REGENXBIO emerged from significant scientific insights in gene therapy. Its foundation rests on pioneering research by James M. Wilson, M.D., Ph.D., from the University of Pennsylvania, particularly his advancements in AAV vector technology. Kenneth T. Mills was instrumental in establishing the company to commercialize these academic discoveries.
REGENXBIO targets patients with debilitating diseases amenable to gene therapy. Its vision is to improve lives by developing and delivering innovative gene therapies. These treatments aim to halt, reverse, or prevent disease progression, striving to offer curative options for many medical conditions lacking effective therapies.
REGENXBIO has raised $101.0M across 2 funding rounds.
REGENXBIO has raised $101.0M in total across 2 funding rounds.
REGENXBIO Inc. (NASDAQ: RGNX) is a leading clinical-stage biotechnology company developing gene therapies for retinal, metabolic, and neurodegenerative diseases using its proprietary NAV® Technology Platform based on adeno-associated virus (AAV) vectors.[1][2][3] The company builds investigational AAV Therapeutics like RGX-314 for wet age-related macular degeneration (AMD) and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for Mucopolysaccharidosis type II (MPS II), targeting one-time treatments for patients with rare and common genetic disorders.[1][2][3] It serves patients, families, and healthcare providers by addressing unmet needs in gene therapy, while generating revenue from Zolgensma royalties and other licensing agreements, with strong growth momentum shown by pivotal trials, BLA filings (e.g., RGX-121 in 2024), and regulatory submissions expected in H1 2026 for ABBV-RGX-314.[1][3]
Founded as a clinical-stage biotech leveraging AAV vector technology, REGENXBIO emerged from pioneering research into safe, non-immunogenic AAV vectors like AAV7, AAV8, AAV9, and over 100 novel variants, granting it exclusive rights via the NAV Platform.[1][2] The idea stemmed from advancing gene therapy innovation to deliver therapeutic proteins or antibodies for genetic disorders, evolving from early R&D into a pipeline focused on retinal (e.g., wet AMD), neuromuscular (e.g., Duchenne), and neurodegenerative diseases.[1][4] Pivotal early traction includes partnerships like Zolgensma royalties and collaborations (e.g., AbbVie for RGX-314), building a culture centered on patients and results.[2][3]
REGENXBIO rides the explosive growth in gene therapy, a trend shifting from chronic treatments to curative, one-time AAV-based interventions for genetic diseases, fueled by maturing vector tech and regulatory progress.[1][2][4] Timing is ideal amid rising demand for retinal (wet AMD affecting millions), neuromuscular (Duchenne), and rare metabolic disorders, with market forces like aging populations, biotech funding recovery, and FDA nods for AAV therapies (e.g., prior Zolgensma approval) accelerating adoption.[1][3] It influences the ecosystem by licensing NAV tech, enabling partners like Novartis and AbbVie, and advancing suprachoroidal delivery for easier administration, potentially lowering barriers and expanding gene therapy accessibility.[2][3]
REGENXBIO is poised for catalysts like H1 2026 regulatory submissions for ABBV-RGX-314 in wet AMD and ongoing pivotal trials for Duchenne and MPS II, potentially driving approvals and royalties amid gene therapy's maturation.[3] Trends like novel AAV serotypes, less invasive delivery, and pipeline expansion into neurodegeneration will shape its path, with influence growing through platform licensing and one-time cure paradigms transforming biotech. This positions REGENXBIO as a NAV tech leader, fulfilling its mission to innovate life-changing gene therapies from high-level platform to patient impact.[2][4]
REGENXBIO has raised $101.0M in total across 2 funding rounds.
REGENXBIO's investors include Venrock, Vivo Capital, Brookside Capital, ARCH Venture Partners, Canaan Partners, Cormorant Asset Management, Deerfield Management, Foresite Capital, F-Prime Capital, Janus Henderson Investors, Jennison Associates, Perceptive Advisors.
REGENXBIO has raised $101.0M across 2 funding rounds. Most recently, it raised $71.0M Series D in May 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2015 | $71.0M Series D | Venrock, Vivo Capital, Brookside Capital | ARCH Venture Partners, Canaan Partners, Cormorant Asset Management, Deerfield Management, Foresite Capital, F-Prime Capital, Janus Henderson Investors, Jennison Associates, Perceptive Advisors, QVT, RTW Investments, Sectoral Asset Management, Tourbillon Global Ventures |
| Jan 1, 2015 | $30.0M Series C | Venrock, Brookside Capital | ARCH Venture Partners, Deerfield Management, Foxkiser, F-Prime Capital |